Back to Peptides
RecoveryLow Risk

Chonluten

Also known as: Bronchogen, Glu-Asp-Leu

Half-life:
Unknown

Administration Routes

oralsubcutaneous injection
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Tripeptide bioregulator targeting bronchial epithelial cells; normalizes gene expression in bronchial tissue; promotes epithelial regeneration

A Khavinson peptide bioregulator for bronchial and lung tissue. Supports repair of respiratory epithelium, studied for COPD, chronic bronchitis, and post-viral lung damage.

Primary Research Areas

  • bronchial repair
  • lung tissue regeneration
  • respiratory anti-inflammatory

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyNot Evaluated by FDA

Russian peptide bioregulator (Glu-Asp-Lys) from Khavinson Institute. Developed for lung health. No FDA approval, no NDA or IND. Not on any FDA list. Research chemical in US.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Chonluten

No active associated providers listed yet.